Pharmacoproteomics in cardiac hypertrophy and atherosclerosis

Alberto Lazaro; Gloria Alvarez-Llamas; Julio Gallego-Delgado; Fernando de la Cuesta; Julio Osende; M Eugenia G Barderas; Fernando Vivanco

doi:10.2174/187152909788488672

Pharmacoproteomics in cardiac hypertrophy and atherosclerosis

Cardiovasc Hematol Disord Drug Targets. 2009 Jun;9(2):141-8. doi: 10.2174/187152909788488672.

Authors

Alberto Lazaro¹, Gloria Alvarez-Llamas, Julio Gallego-Delgado, Fernando de la Cuesta, Julio Osende, M Eugenia G Barderas, Fernando Vivanco

Affiliation

¹ Laboratory of Renal Physiopathology, Nephrology Department, Gregorio Marañón University General Hospital, Madrid, Spain.

PMID: 19519373
DOI: 10.2174/187152909788488672

Abstract

Proteomics applications to study the molecular effects of drug administration (pharmacoproteomics) on left ventricular hypertrophy (LVH) and atherosclerosis are here reviewed. In most cases, an absence of complete normalization after treatment is revealed, in contrast to what is reported by classical approaches.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antihypertensive Agents / therapeutic use
Atherosclerosis / drug therapy*
Atherosclerosis / metabolism*
Calcium Channel Blockers / therapeutic use
Dose-Response Relationship, Drug
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hypertrophy, Left Ventricular / drug therapy*
Hypertrophy, Left Ventricular / metabolism*
Myocardium / metabolism
Proteome / metabolism*
Proteomics

Substances

Antihypertensive Agents
Calcium Channel Blockers
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Proteome